Literature DB >> 16947084

Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Deepali Sachdev1, Douglas Yee.   

Abstract

The peptide growth factors IGF-I and IGF-II not only play a role in the development of the mammary gland but are also implicated in breast cancer. Several reagents disrupting IGF signaling have been developed and clinical trials validating IGF signaling as a target in cancer therapy are underway. This review highlights the approaches to inhibiting IGF signaling in breast cancer.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16947084     DOI： 10.1007/s10911-006-9010-8

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN： 1083-3021            Impact factor:   2.673


  98 in total

1.  In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.

Authors:  Jennifer D Wu; Austin Odman; Lily M Higgins; Kathy Haugk; Robert Vessella; Dale L Ludwig; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

2.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Authors:  Joan M Carboni; Adrian V Lee; Darryl L Hadsell; Bruce R Rowley; Francis Y Lee; David K Bol; Amy E Camuso; Marco Gottardis; Ann F Greer; Ching Ping Ho; Warren Hurlburt; Aixin Li; Mark Saulnier; Upender Velaparthi; Cindy Wang; Mei-Li Wen; Richard A Westhouse; Mark Wittman; Kurt Zimmermann; Brent A Rupnow; Tai W Wong
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 3.  The place of pegvisomant in the management of acromegaly.

Authors:  C Parkinson; P J Trainer
Journal:  Expert Opin Investig Drugs       Date:  2001-09       Impact factor: 6.206

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status.

Authors:  J A Figueroa; J G Jackson; W L McGuire; R F Krywicki; D Yee
Journal:  J Cell Biochem       Date:  1993-06       Impact factor: 4.429

6.  In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen.

Authors:  H T Huynh; E Tetenes; L Wallace; M Pollak
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

7.  Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Authors:  Ada Girnita; Leonard Girnita; Fabrizio del Prete; Armando Bartolazzi; Olle Larsson; Magnus Axelson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

8.  Local insulin-like growth factor-II mediates prolactin-induced mammary gland development.

Authors:  Russell C Hovey; Jessica Harris; Darryl L Hadsell; Adrian V Lee; Christopher J Ormandy; Barbara K Vonderhaar
Journal:  Mol Endocrinol       Date:  2002-12-23

9.  Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.

Authors:  Mariana Salatino; Roxana Schillaci; Cecilia J Proietti; Romina Carnevale; Isabel Frahm; Alfredo A Molinolo; Adolfo Iribarren; Eduardo H Charreau; Patricia V Elizalde
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

Review 10.  Somatostatin analogs for diagnosis and treatment of cancer.

Authors:  G Weckbecker; F Raulf; B Stolz; C Bruns
Journal:  Pharmacol Ther       Date:  1993-11       Impact factor: 12.310
View more
  27 in total

1.  Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.

Authors:  Ping Li; Artour Torossian; Qing Zhang; Wen-Cai Xu; Shen Fu
Journal:  Med Oncol       Date:  2012-06-23       Impact factor: 3.064

Review 2.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

3.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

4.  Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Authors:  Iván P Uray; Qiang Shen; Hye-Sook Seo; HeeTae Kim; William W Lamph; Reid P Bissonnette; Powel H Brown
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

5.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

6.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Authors:  Liang Cao; Yunkai Yu; Isaac Darko; Duane Currier; Linnia H Mayeenuddin; Xiaolin Wan; Chand Khanna; Lee J Helman
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

7.  Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation.

Authors:  H Zhang; D H Fagan; X Zeng; K T Freeman; D Sachdev; D Yee
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

8.  Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways.

Authors:  Cemal Erdem; Alison M Nagle; Angelo J Casa; Beate C Litzenburger; Yu-Fen Wang; D Lansing Taylor; Adrian V Lee; Timothy R Lezon
Journal:  Mol Cell Proteomics       Date:  2016-06-30       Impact factor: 5.911

9.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore.

Authors:  H Zhang; X Zeng; Q Li; M Gaillard-Kelly; C R Wagner; D Yee
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.